Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
Bioorganic & Medicinal Chemistry Letters
|
June 12, 2009
Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas
Terance Hart, Alba T Macias, Karen Benwell, et al.
Cancer Chemotherapy and Pharmacology
|
December 17, 2009
A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells
Andrew J Massey, Douglas S Williamson, Helen Browne, et al.
Journal of Medicinal Chemistry
|
April 30, 2011
Adenosine-derived inhibitors of 78 kDa glucose regulated protein (Grp78) ATPase: insights into isoform selectivity
Alba T Macias, Douglas S Williamson, Nicola Allen, et al.
RSC Medicinal Chemistry
|
November 25, 2022
PAC-FragmentDEL - photoactivated covalent capture of DNA-encoded fragments for hit discovery
Huiyong Ma, James B Murray, Huadong Luo, et al.
ACS Omega
|
August 29, 2019
Establishing Drug Discovery and Identification of Hit Series for the Anti-apoptotic Proteins, Bcl-2 and Mcl-1
James B Murray, James Davidson, Ijen Chen, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 3, 2012
Fatty acid amide hydrolase inhibitors. 3: tetra-substituted azetidine ureas with in vivo activity
Stephen D Roughley, Helen Browne, Alba T Macias, et al.
Bioorganic & Medicinal Chemistry
|
September 29, 2012
Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization
Nicholas G M Davies, Helen Browne, Ben Davis, et al.
Journal of Medicinal Chemistry
|
February 16, 2017
Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase
Paul A Brough, Lisa Baker, Simon Bedford, et al.
Oncotarget
|
May 8, 2018
S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth
Patrick Casara, James Davidson, Audrey Claperon, et al.
Nature
|
October 28, 2016
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
András Kotschy, Zoltán Szlavik, James Murray, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
Bioorganic & Medicinal Chemistry Letters
|
June 12, 2009
Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas
Terance Hart, Alba T Macias, Karen Benwell, et al.
Cancer Chemotherapy and Pharmacology
|
December 17, 2009
A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells
Andrew J Massey, Douglas S Williamson, Helen Browne, et al.
Journal of Medicinal Chemistry
|
April 30, 2011
Adenosine-derived inhibitors of 78 kDa glucose regulated protein (Grp78) ATPase: insights into isoform selectivity
Alba T Macias, Douglas S Williamson, Nicola Allen, et al.
RSC Medicinal Chemistry
|
November 25, 2022
PAC-FragmentDEL - photoactivated covalent capture of DNA-encoded fragments for hit discovery
Huiyong Ma, James B Murray, Huadong Luo, et al.
ACS Omega
|
August 29, 2019
Establishing Drug Discovery and Identification of Hit Series for the Anti-apoptotic Proteins, Bcl-2 and Mcl-1
James B Murray, James Davidson, Ijen Chen, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 3, 2012
Fatty acid amide hydrolase inhibitors. 3: tetra-substituted azetidine ureas with in vivo activity
Stephen D Roughley, Helen Browne, Alba T Macias, et al.
Bioorganic & Medicinal Chemistry
|
September 29, 2012
Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization
Nicholas G M Davies, Helen Browne, Ben Davis, et al.
Journal of Medicinal Chemistry
|
February 16, 2017
Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase
Paul A Brough, Lisa Baker, Simon Bedford, et al.
Oncotarget
|
May 8, 2018
S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth
Patrick Casara, James Davidson, Audrey Claperon, et al.
Nature
|
October 28, 2016
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
András Kotschy, Zoltán Szlavik, James Murray, et al.
Page
of 2